Drug intelligence / Profile preview

ASP0739 + pembrolizumab

Development stage: Unknown
Lead developer: Astellas Pharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**ASP0739 + pembrolizumab** is a combination of an investigational cancer immunotherapy (ASP0739) and the checkpoint inhibitor pembrolizumab. ASP0739 is developed for advanced solid tumors known to express NY-ESO-1 antigen. ASP0739 is believed to be a monoclonal antibody or immune-modulating agent (precise modality not fully disclosed) targeting cancer/testis antigens such as CTAG1B (NY-ESO-1). Pembrolizumab is a programmed cell death protein 1 (PD-1) inhibitor that reactivates T-cells to enhance anti-tumor immune responses. The primary indication for the combination is advanced, relapsed/refractory solid tumors expressing NY-ESO-1, such as synovial sarcoma and myxoid/round cell liposarcoma.

Other names: ASP0739 + Keytruda

Targets

NY-ESO-1 (New york esophageal squamous cell carcinoma 1)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on ASP0739 + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASP0739 + pembrolizumab.

Explore the full profile